NCT01689987View on ClinicalTrials.gov

Hydroxychloroquine, Cyclophosphamide, Dexamethasone, and Sirolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

April 30, 2016

Conditions

Recurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma

Interventions

DRUG

Cyclophosphamide

Given IV

DRUG

Dexamethasone

Given PO

DRUG

Hydroxychloroquine

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Pharmacological Study

Correlative studies

DRUG

Sirolimus

Given PO

Trial Locations (1)

97239

OHSU Knight Cancer Institute, Portland

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

OHSU Knight Cancer Institute

OTHER

NCT01689987 - Hydroxychloroquine, Cyclophosphamide, Dexamethasone, and Sirolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma | Biotech Hunter | Biotech Hunter